Simple scoring system predicting genotypic resistance during rescue therapy for lamivudine-resistant chronic hepatitis B

Journal of Clinical Gastroenterology

Volumn 46, Issue 3, 2012, Pages 243-250

  Lee, Jeong Hoon ^a   Yoon, Jung Hwan ^a   Cho, Eun Ju ^a   Yang, Hyo Joon ^a   Jang, Eun Sun ^a   Kwak, Min Sun ^a   Hwang, Sang Youn ^a   Yu, Su Jong ^a   Lee, Chang Hoon ^a   Kim, Yoon Jun ^a   Kim, Chung Yong ^a   Lee, Hyo Suk ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Antiviral Resistance Prediction Index; chronic hepatitis B; genotypic resistance; rescue therapy

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; VIRUS DNA;

ADULT; AGED; ANTIVIRAL RESISTANCE PREDICTION INDEX; ARTICLE; CHRONIC HEPATITIS; DRUG RESPONSE; DRUG SUBSTITUTION; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; TREATMENT DURATION; VIRUS GENE; VIRUS LOAD; VIRUS RESISTANCE;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857048627     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318225f559     Document Type: Article

References (21)

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507-539. (Pubitemid 46374607)
2. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol. 2004;19:1276-1282.
3. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714-1722. (Pubitemid 37500436)
4. Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis. 2005;25 (suppl 1):9-19. (Pubitemid 41254589)
5. Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology. 1999;30: 567-572.
6. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-242.
7. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661-662.
8. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283.
9. Lee KS, Kim DJ. Management of chronic hepatitis B. Korean J Hepatol. 2007;13:447-488.
10. Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAgnegative chronic hepatitis B. Hepatology. 2007;45:307-313. (Pubitemid 46374587)
11. Fung J, Lai CL, Yuen JC, et al. Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. Antivir Ther. 2007;12:41-46. (Pubitemid 46340424)
12. Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 2007;133:1445-1451. (Pubitemid 350047463)
13. Kim HJ, Park JH, Park DI, et al. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol. 2010;25:1374-1380.
14. Ryu HJ, Lee JM, Ahn SH, et al. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol. 2010;82:1835-1842.
15. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007;46:254-265. (Pubitemid 47171942)
16. Hochberger S, Althof D, Gallegos de Schrott R, et al. Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol. 2006;35:373-380. (Pubitemid 43324832)
17. Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology. 2008;48:99-108. (Pubitemid 351975535)
18. Shim JH, Suh DJ, Kim KM, et al. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology. 2009;50: 1064-1071.
19. Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther. 2004;9:679-693. (Pubitemid 39434331)
20. Lee JM, Kim HJ, Park JY, et al. Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. Antivir Ther. 2009;14: 705-712.
21. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442-2455.